Amgen "overweight," target price reduced

24.03.07 - Lehman Brothers

NEW YORK, March 24 (newratings.com) - In a research note published yesterday, analysts at Lehman Brothers reiterate their "overweight" rating on Amgen (AMGN). The target price has been reduced from $91 to $86.